These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 29886833)
1. Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib. Milan A; Bruno G; Maffei I; Iannaccone A; Ravera A; Schiavone D; Veglio F Curr Hypertens Rev; 2019; 15(1):47-53. PubMed ID: 29886833 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365 [TBL] [Abstract][Full Text] [Related]
3. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. Bishnoi R; Xie Z; Shah C; Bian J; Murthy HS; Wingard JR; Farhadfar N Cancer Med; 2021 Jan; 10(1):70-78. PubMed ID: 33169938 [TBL] [Abstract][Full Text] [Related]
4. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. Bringhen S; Milan A; D'Agostino M; Ferri C; Wäsch R; Gay F; Larocca A; Offidani M; Zweegman S; Terpos E; Goldschmidt H; Cavo M; Ludwig H; Driessen C; Auner HW; Caers J; Gramatzki M; Dimopoulos MA; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M J Intern Med; 2019 Jul; 286(1):63-74. PubMed ID: 30725503 [TBL] [Abstract][Full Text] [Related]
5. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. Gavazzoni M; Lombardi CM; Vizzardi E; Gorga E; Sciatti E; Rossi L; Belotti A; Rossi G; Metra M; Raddino R Eur J Pharmacol; 2018 Nov; 838():85-90. PubMed ID: 30201379 [TBL] [Abstract][Full Text] [Related]
6. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Martin TG Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230 [TBL] [Abstract][Full Text] [Related]
7. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib. Siegel DS Oncology (Williston Park); 2013 Dec; 27 Suppl 3():2-3. PubMed ID: 25184229 [No Abstract] [Full Text] [Related]
8. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Shah JJ Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232 [TBL] [Abstract][Full Text] [Related]
9. A practical review on carfilzomib in multiple myeloma. Muchtar E; Gertz MA; Magen H Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241 [TBL] [Abstract][Full Text] [Related]
10. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma. Steele JM J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972 [TBL] [Abstract][Full Text] [Related]
11. Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Wang M; Cheng J Oncology (Williston Park); 2013 Dec; 27 Suppl 3():24-30. PubMed ID: 25184233 [TBL] [Abstract][Full Text] [Related]
12. Pulmonary arterial hypertension in a patient with multiple myeloma during carfilzomib treatment: in search of better management. Rago A; Siniscalchi A; Tordi A; Andrizzi C; Campagna S; Caravita di Toritto T Tumori; 2021 Dec; 107(6):NP37-NP40. PubMed ID: 33525991 [TBL] [Abstract][Full Text] [Related]
14. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Nooka AK Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231 [TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma. Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316 [TBL] [Abstract][Full Text] [Related]
16. Carfilzomib: a novel agent for multiple myeloma. Redic K J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578 [TBL] [Abstract][Full Text] [Related]
17. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. McBride A; Klaus JO; Stockerl-Goldstein K Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410 [TBL] [Abstract][Full Text] [Related]